MaxCyte inks deal with South Korea's Curamys
5th Dec 2022 13:28
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence with South Korea-based biotechnology specialist Curamys on Monday, which develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Read moreMaxCyte revenues improve in third quarter
10th Nov 2022 13:06
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total third-quarter revenue of $10.6m on Thursday, making for an increase of 5% year-on-year.
Read moreMaxCyte hikes guidance after solid first half
11th Aug 2022 14:31
(Sharecast News) - Cell engineering company MaxCyte reported total first-half revenue of $21.2m on Thursday, up 56% year-on-year, as it increased its guidance for the full year.
Read moreMaxCyte reports good first quarter revenue growth
10th May 2022 11:18
(Sharecast News) - Cell engineering technology company MaxCyte reported total first quarter revenue of $11.6m (£9.42m) in an update on Tuesday - an increase of 78% year-on-year.
Read moreMaxCyte CFO resigns, first quarter revenues rise
13th Apr 2022 10:45
(Sharecast News) - Cell engineering company MaxCyte announced on Wednesday that Amanda Murphy has resigned from her position as chief financial officer as of 15 April, to "pursue other interests".
Read moreMaxCyte reports record Q4 and full-year revenue
23rd Mar 2022 12:06
(Sharecast News) - Cell engineering company MaxCyte reported record quarterly revenue of $10.2m (£7.73m) for the final three months of 2021 on Wednesday, up 19% year-on-year.
Read moreMaxCyte taps Cenk Sumen as its chief scientific officer
10th Mar 2022 11:17
(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Cenk Sumen as its chief scientific officer on Thursday.
Read moreMaxCyte to consolidate its restricted and unrestricted shares
21st Feb 2022 10:01
(Sharecast News) - Cell engineering technology company MaxCyte announced the consolidation of the two lines of its common stock into a single unrestricted line of common stock on Monday.
Read moreMaxCyte signs platform licence with biotech firm Intima
1st Feb 2022 12:51
(Sharecast News) - Cell engineering platform technology company MaxCyte announced the signing of a strategic platform licence (SPL) with Intima Bioscience on Tuesday.
Read moreMaxCyte ends year with strong trading
24th Jan 2022 09:35
(Sharecast News) - Cell engineering company MaxCyte said on Monday that it expected total revenue for its fourth quarter to be at least $10m, up from $8.5m year-on-year, reflecting growth of at least 17% in total revenue and at least 37% in core business revenue.
Read moreDirector dealings: Maxcyte chairman makes share purchase
23rd Nov 2021 15:25
(Sharecast News) - Maxcyte revealed on Tuesday that chairman Richard Douglas had acquired 20,000 ordinary shares in the AIM-listed cell-engineering company.
Read moreMaxCyte revenue jumps more than 50pc in third quarter
11th Nov 2021 11:58
(Sharecast News) - Commercial cell engineering company MaxCyte reported total third quarter revenue of $10.1m in an update on Thursday, representing 50% growth compared to the same period in 2020.
Read moreMaxCyte announces pricing of upsized Nasdaq share offering
30th Jul 2021 12:25
(Sharecast News) - Cell engineering technology company MaxCyte announced the pricing of its upsized offering of 13,500,000 shares on Nasdaq on Friday, at a price of $13.00 per share.
Read moreMaxCyte signs strategic partnership with Celularity
25th May 2021 11:45
(Sharecast News) - Cell-based therapy developer MaxCyte announced the signing of a strategic platform licence with clinical-stage biotechnology company Celularity on Tuesday.
Read moreMaxCyte proposes dual listing on Nasdaq
14th May 2021 09:05
(Sharecast News) - Cell engineering technology company MaxCyte has submitted a draft registration statement with the Securities and Exchange Commission (SEC), it announced on Friday, for a proposed dual-listing and public offering of shares on the Nasdaq market.
Read more